Inavolisib Demonstrates Safety, Disease Control in PIK3CA-Mutated Solid Tumors
Treatment with inavolisib (GDC-0077) demonstrated a favorable safety profile and led to disease control in patients with refractory locally advanced or metastatic solid tumors harboring PIK3CA mutations, according to data from the phase 2 CRAFT trial ( …